Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (15 quarters reported)
$135M in Q2 2013 → $93M now. Hover for any quarter.
As reported for the quarter ended December 31, 2016. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| DT Dbv Technologies | 33.5% | Unchanged | 456,893 | $31.1M |
| Heron Therapeutics Inc | 15.4% | Unchanged | 1,095,734 | $14.4M |
| CB Coherus Biosciences Inc | 9.2% | Unchanged | 305,505 | $8.6M |
| Biocryst Pharmaceuticals Inc | 7.9% | Added 15% | 1,155,104 | $7.31M |
| Avadel Pharmaceuticals | 5.6% | Unchanged | 500,000 | $5.2M |
| RP Ra Pharmaceuticals | 3.8% | New | 232,500 | $3.53M |
| Adverum Biotechnologies | 3.4% | Unchanged | 1,102,735 | $3.2M |
| Lipocine Inc | 3.4% | Unchanged | 849,921 | $3.13M |
| CP Colucid Pharmaceuticals | 2.7% | Unchanged | 68,190 | $2.48M |
| AS Axovant Sciences Ltd | 2.5% | Unchanged | 184,110 | $2.29M |
| OT Ocera Therapeutics | 2.1% | Added 6.5% | 912,050 | $1.92M |
| Ascendis Pharma A/s | 2.0% | Unchanged | 90,000 | $1.82M |
| ET Edge Therapeutics Inc | 1.8% | Unchanged | 135,000 | $1.69M |
| ST Stemline Therapeutics Inc | 1.6% | Unchanged | 135,420 | $1.45M |
| A Alcobra Ltd | 1.5% | Unchanged | 658,910 | $1.38M |
| AB Arca Biopharma Inc | 1.4% | Unchanged | 462,399 | $1.32M |
| Akari Therapeutics PLC | 1.2% | Unchanged | 158,352 | $1.12M |
| Cytomx Therapeutics Inc | 0.8% | Unchanged | 64,200 | $706K |
| AT Audentes Therapeutics | 0.3% | Unchanged | 15,000 | $274K |
| PT Pronai Therapeutics Inc | 0.1% | Unchanged | 56,056 | $84K |
| AB Aeglea Biotherapeutics | 0.0% | Unchanged | 6,000 | $26K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended December 31, 2016 · filed February 13, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| RP Ra Pharmaceuticals | New | +232,500 | +$3.53M | 3.8% |
| Z Zafgen Inc | Exited | −602,114 | −$1.99M | — |
| B Beigene Ltd | Exited | −51,000 | −$1.57M | — |
| AP Achillion Pharmaceuticals Inc | Exited | −180,000 | −$1.46M | — |
| Biocryst Pharmaceuticals Inc | Added | +150,000 | +$950K | 7.9% |
| Regenxbio Inc | Exited | −24,089 | −$337K | — |
| OT Ocera Therapeutics | Added | +55,500 | +$117K | 2.1% |
quarter ended September 30, 2016 · filed November 14, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CB Coherus Biosciences Inc | Trimmed | −305,505 | −$8.18M | 8.0% |
| CP Colucid Pharmaceuticals | New | +68,190 | +$2.6M | 2.6% |
| CT Cynapsus Therapeutics Inc | Exited | −108,575 | −$1.81M | — |
| AP Achillion Pharmaceuticals Inc | New | +180,000 | +$1.46M | 1.4% |
| GB Global Blood Therapeutics | Exited | −72,990 | −$1.21M | — |
| Regenxbio Inc | Trimmed | −28,411 | −$397K | 0.3% |
| AT Audentes Therapeutics | New | +15,000 | +$267K | 0.3% |
| OT Ocera Therapeutics | Added | +60,000 | +$158K | 2.2% |
| A Alcobra Ltd | Added | +35,597 | +$88K | 1.6% |
quarter ended June 30, 2016 · filed August 12, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Anacor Pharmaceuticals Inc | Exited | −140,756 | −$7.52M | — |
| AB Avalanche Biotechnologies Inc | Exited | −1,102,735 | −$5.7M | — |
| Adverum Biotechnologies | New | +1,102,735 | +$3.49M | 3.6% |
| Biocryst Pharmaceuticals Inc | Added | +442,161 | +$1.26M | 3.0% |
| A Alcobra Ltd | Added | +138,813 | +$623K | 2.9% |
| AB Aeglea Biotherapeutics | New | +6,000 | +$29K | — |
quarter ended March 31, 2016 · filed May 13, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| GP Gw Pharmaceuticals | Exited | −311,853 | −$21.7M | — |
| AS Axovant Sciences Ltd | New | +184,110 | +$2.11M | 1.8% |
| Biocryst Pharmaceuticals Inc | New | +562,943 | +$1.59M | 1.4% |
| B Beigene Ltd | New | +51,000 | +$1.5M | 1.3% |
| DT Dbv Technologies | Trimmed | −6,750 | −$429K | 25.2% |
| Z Zafgen Inc | Added | +60,634 | +$405K | 3.5% |
| OT Ocera Therapeutics | Added | +92,820 | +$273K | 2.0% |
| GB Global Blood Therapeutics | Added | +12,299 | +$195K | 1.0% |
| Cytomx Therapeutics Inc | Trimmed | −10,800 | −$139K | 0.7% |
| PT Pronai Therapeutics Inc | Trimmed | −18,944 | −$128K | 0.3% |
Showing the 10 largest of 11 changes.
quarter ended December 31, 2015 · filed February 12, 2016
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Anacor Pharmaceuticals Inc | Trimmed | −1,037,718 | −$117M | 9.6% |
| Regenxbio Inc | Trimmed | −1,030,954 | −$17.1M | 0.5% |
| DT Dbv Technologies | Trimmed | −230,167 | −$16.1M | 19.6% |
| Ascendis Pharma A/s | Trimmed | −721,152 | −$13.2M | 1.0% |
| A Alcobra Ltd | Trimmed | −1,015,500 | −$6.38M | 1.8% |
| CB Coherus Biosciences Inc | Trimmed | −259,259 | −$5.95M | 8.5% |
| Lipocine Inc | Trimmed | −420,000 | −$5.43M | 6.6% |
| Akari Therapeutics PLC | Trimmed | −369,490 | −$5.36M | 1.4% |
| AB Arca Biopharma Inc | Trimmed | −1,078,932 | −$5.02M | 1.3% |
| CT Cynapsus Therapeutics Inc | Trimmed | −257,201 | −$3.97M | 1.0% |
Showing the 10 largest of 16 changes.
quarter ended September 30, 2015 · filed November 13, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AB Arca Biopharma Inc | Trimmed | −9,247,993 | −$45.9M | 2.0% |
| Regenxbio Inc | New | +1,083,454 | +$20.2M | 5.2% |
| Akari Therapeutics PLC | New | +527,842 | +$12.7M | 3.2% |
| Biocryst Pharmaceuticals Inc | Exited | −373,686 | −$5.58M | — |
| ZP Zs Pharma Inc | Exited | −100,000 | −$5.24M | — |
| PT Pronai Therapeutics Inc | New | +250,000 | +$5.13M | 1.3% |
| JT Juno Therapeutics Inc | Exited | −90,206 | −$4.81M | — |
quarter ended June 30, 2015 · filed August 13, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JT Juno Therapeutics Inc | Trimmed | −1,659,793 | −$88.5M | 1.4% |
| CT Cynapsus Therapeutics Inc | Trimmed | −5,511,428 | −$88.4M | 1.7% |
| Biocryst Pharmaceuticals Inc | Trimmed | −1,370,670 | −$20.5M | 1.6% |
| D Dyax Corp | Exited | −1,000,659 | −$16.8M | — |
| AB Arca Biopharma Inc | New | +10,789,324 | +$12.4M | 3.5% |
| Lipocine Inc | Added | +600,000 | +$5.15M | 3.1% |
| Therapeuticsmd Inc | Exited | −846,500 | −$5.12M | — |
quarter ended March 31, 2015 · filed May 14, 2015
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ascendis Pharma A/s | New | +811,152 | +$12.9M | 3.0% |
| RH Radius Health Inc | Exited | −233,294 | −$9.08M | — |
| A Alcobra Ltd | New | +1,500,000 | +$8.45M | 1.9% |
| OP Ohr Pharmaceutical | Exited | −477,000 | −$3.98M | — |
| CT Cynapsus Therapeutics Inc | Added | +4,342,105 | +$3.78M | 1.2% |
| ST Stemline Therapeutics Inc | Added | +95,000 | +$1.37M | 1.5% |
| SP Sunesis Pharmaceuticals | Exited | −536,189 | −$1.37M | — |
Loading...
